AbbVie acquires Gilgamesh Pharmaceuticals, Inc.

AbbVie acquired Gilgamesh Pharmaceuticals, Inc. for $906 million upfront, a transaction completed in July 2025, structured as all cash (upfront plus potential milestones).

Gilgamesh Pharmaceuticals, Inc. operates in Neuroscience (psychiatry), is based in New York, New York. AbbVie completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, a novel short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser (psychedelic-class) compound in Phase 2 development for major depressive disorder. The FY2025 10-K records approximately $906 million of upfront charges. (Reported completed in Q3 2025.)

Adds a differentiated, short-acting neuropsychiatric candidate to AbbVie's neuroscience pipeline.

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.